Crescent Biopharma (CBIO) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Neurogene (NGNE) over the past year, gaining 19.5% versus a gain of 10.2%. Over five years, NGNE leads with a -82.1% price change compared with -93.2% for CBIO. Neurogene is the larger company by market cap ($517.7 million vs $501.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | NGNE |
|---|---|---|
| Share price | $13.49 | $25.87 |
| Market cap | $501.11M | $517.69M |
| 1-day change | -0.59% | +1.65% |
| YTD return | +13.74% | +25.58% |
| 1-year return | +19.49% | +10.23% |
| 5-year return | -93.19% | -82.08% |
| EPS (TTM) | $-7.63 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $43.66 |
| 52-week low | $8.72 | $15.93 |
| Distance from 52-week high | -50.78% | -40.75% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +133.51% | +210.90% |
| Average volume | 397.58K | 245.99K |
| Shares outstanding | 37.14M | 20.01M |
| Employees | 69 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
CBIO vs NGNE FAQ
Which is bigger, Crescent Biopharma or Neurogene?
Neurogene (NGNE) is larger, with a market capitalization of $517.69M compared with $501.11M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, CBIO or NGNE?
CBIO returned +19.49% over the past 12 months, compared with +10.23% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.